semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Burning Mouth Syndrome diagnosis of burning mouth syndrome in accordance the International Classification of Headaches: continuous symptoms of oral burning or pain on a daily or almost daily basis, during all or part of the day for more than 6 months  history of head and neck malignancy, radiation therapy to the head and neck area, poorly managed diabetes mellitus, chronic thyroid disease, or known Sjogren's disease and pregnant
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Soft Tissue Lesions Patient scheduled for clinically indicated conventional Ultrasound examination  Age < 18 years
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Myasthenia Gravis Patients between18 to 80 years of age, diagnosed with MG (see below) who have worsening myasthenic symptoms (defined as increasing diplopia, ptosis, dysarthria, dysphagia, difficulty chewing, or limb weakness severe enough to warrant immunoglobulin therapy MG diagnosis will be based upon the clinical evaluation by a neuromuscular expert and meeting any two of the following supportive 1. Abnormal Tensilon test 2. Abnormal repetitive nerve stimulation studies 3. Abnormal single fiber electromyography (EMG) 4. Increased serum acetylcholine receptor or anti-MuSK antibodies 5. Prior response to immunotherapy  Respiratory distress requiring ICU admission or a vital capacity <1 L 2. Severe swallowing difficulties with a high risk of aspiration 3. Change in corticosteroid dosage in the 4 weeks prior to screening 4. Known immunoglobulin A (IgA) deficiency 5. Pregnant or breast feeding women 6. Active renal or hepatic insufficiency, clinically significant cardiac disease 7. Patients with worsening weakness associated with an infectious process 8. Previous lack of responsiveness to IVIG 9. History of previous MG crises
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-80.0,  Diabetes Mellitus Study patients should meet the following for in the study: 1. 100 Chinese, 100 Malays, 100 Indian patients with DM2 2. Age 21-80 years 3. Able to give informed consent 4. Stable diabetes, blood pressure and hyperlipidaemia medications (a 25% dose adjustment is allowed) in the last three months 5. For to be randomized: HbA1c should be 10% inclusive or below at time of randomisation 6. Blood Pressure should be less than 180/120 mm Hg at time of recruitment 7. Non-smokers or discontinued smoking at least 6 months ago 8. No h/o previous myocardial infarction, previous cerebrovascular accident inclusive of haemorrhage and infarction, or h/o of peripheral amputation or bypass procedures  Inability to give informed consent 2. Pregnant subjects 3. Patients hospitalized for any condition less than 1 month from enrolment 4. Patients having any recent infections or symptoms suggestive of any systemic infection in the last 2 weeks 5. Myocardial Infarction or stroke within 6 months before enrolment 6. Patients with creatinine concentrations >200 µmol/L or eGFR<30 µmol/L 7. Patients on anticoagulants such as warfarin 8. Known allergy to vitamin E 9. Current smokers 10. h/o previous myocardial infarction, previous cerebrovascular accident inclusive of haemorrhage and infarction, or h/o of peripheral amputation or bypass procedures 11. Patients on immunosuppressive agents or corticosteroids for other conditions 12. Presence of concomitant malignancies or rheumatological conditions at the time of recruitment 13. Patients taking orlistat & cholestyramine
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Type 2 Diabetes Men and women aged greater than 40 years Patients requiring surgery of the lower limb With a bone mineral density considered normal (T-score ≥ -2) Stage 1, 2, or 3 glomerular filtration rate (> 30 mL/min) For diabetic patients the diagnosis will have previously established by an endocrinologist  Subjects treated with drugs known to interfere with bone metabolism, including steroids, anticonvulsants, diuretics, and bisphosphonates Patients with severe renal disease (< 30 ml/mn); previous history of caner except skin cancer; myocardial infarction; uncontrolled hypertension; untreated hyperthyroidism; hyperthyroidism; malabsorption; bone metabolism diseases; rheumatoid arthritis or collagen diseases Pregnant or lactating woman Contraindication to taking tetracycline hydrochloride Known hypersensitivity to antibiotics of the tetracycline family or any of the excipients in the medicine Severe chronic renal failure Chronic liver failure Systemic lupus erythematosus Concomitant prescription of retinoid or vitamin A (risk intracranial hypertension) Psychiatric pathology seriously hampering understanding
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Paget's Disease of Bone for Cases Men and women between the ages of 18-99 years who have evidence of active Paget's disease of bone as clinically and/or radiographically defined by Increased serum alkaline phosphatase or increased serum collagen type 1 c-telopeptide (CTX) or increase in urinary pyridinoline at diagnosis AND history of at least one of the following signs/symptoms: Pagetoid lesions(s) on x-ray/CT/MRI, increased uptake of radioactive substance by bone scan, bone pain, fracture, hearing loss, headache, hypercalcemia, or bony deformity. for controls Men and women between the ages of 18-99 years who match age within 5 years of cases and gender who do NOT have evidence of Paget's disease of bone as defined by No bone pain or bony deformity Normal serum alkaline phosphatase  Osteosarcoma or other blastic bony metastases alone Fibrous dysplasia of bone Hyperostosis frontalis interna All men and women < 18 years or > 99 years Pregnancy (women) determined by self-report Current use of oral contraceptive tablets or Depo-Provera™ (women) Current use of hormone replacement therapy Creatinine clearance < 60 ml/min./1.73 m2 by Cockcroft-Gault based on most recent serum creatinine level (if greater than 1 year since last assessment, will be measured on collected blood sample to verify eligibility) Current smoking or tobacco use Alcohol use greater than 3 units daily
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Vertigo Diseases, Vestibular Caffeine Medical students volunteers Had no hearing and/or vestibular complaints  Problems in the cervical spine Cardiovascular problems Migraine Metabolic disorders Hormonal changes Psychiatric disorders Neurological diseases Use of prescription drugs continuously Smokers Alcoholics
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Impacted Third Molar Tooth Patients age between 18 and 50 years Patients who required mandibular 3rd molar extractions Patients had to have clinical and radiographic diagnosis of a single impacted mandibular third molar Radiographic diagnosis of Class II position B impaction (Pell and Gregory classification) Patients agree to return for recall visits Patients who were not experienced pain, inflammation, and infection at the operating site 7 days before the surgery  criterion Patients if pregnant, lactating, or smokers or if they had systemic disease or any other medications that could interfere with healing process Any antibiotic or any anti-inflammatory drug usage within a week period Patients with any periapical infection or lesion associated with the third molars Patients with unacceptable oral hygiene
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 35.0-85.0,  Osteoarthritis, Knee Voluntary signature of the IRB approved Informed Consent 2. Unilateral or bilateral osteoarthritic male or female ages 35-85 3. Pain, swelling, and/or functional disability in the affected knee consistent with osteoarthritis in the knee joint 4. Physical examination consistent with osteoarthritis in one knee joint 5. Kellgren-Lawrence grade 2 or greater knee osteoarthritis and/or diagnostic MRI imaging of the affected knee showing osteoarthritis (i.e. chondral loss, fissuring, defect, bone marrow lesion, meniscus tear, synovial thickening, etc…) 6. Is independent, ambulatory, and can comply with all post-operative evaluations and visits  Knee injections of any type within 3 months prior to the study. 2. Knee surgery within 6 months prior to the study. 3. Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout) 4. Quinolone or Statin induced myopathy/tendinopathy 5. Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh 6. Contraindications for MRI 7. Condition represents a worker's compensation case 8. Currently involved in a health-related litigation procedure 9. Is pregnant 10. Bleeding disorders 11. Currently taking anticoagulant or immunosuppressive medication 12. Allergy or intolerance to study medication 13. Use of chronic opioid 14. Documented history of drug abuse within six months of treatment 15. Any other condition, that in the opinion of the investigator, that would preclude the patient from enrollment
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metabolic Bone Disease intestinal failure requiring home parental nutrition bone disease measurement  intestinal failure not requiring HPN diagnostic modalities impossible
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Acute Hepatitis of 101 test subjects and for statistical analysis patients with non-acute severe hepatitis (TP> 50% and AST or ALT> 500 IU / L or> 10 xN for less than 15 days) patients with severe acute hepatitis (TP <50%). Patients with suspected IS with the assay of the CTS will retested at Synacthène 4 to 6 months later (10 desired subjects) healthy volunteers (control group included in the analysis) of 10 patients with established IS (control group to estimate the low values of cortisol) Patient who signed the consent of study participation  Women during pregnancy or breastfeeding Minor and over 75 years Major protected within the meaning of Huriet Subject healthy volunteers in a sport competition Patients transplanted, HIV infection (also refusing HIV status) or patients on immunosuppressive therapies (including corticosteroids) ketoconazole Shot, rifampicin, mifepristone, megestrol or etomidate Treatment with corticosteroids irrespective of the route of administration severe acute alcoholic hepatitis oral fungal infection upper gastrointestinal bleeding or oral bleeding (contamination salivettes)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Female Sexual Dysfunction Polycystic Ovary Syndrome Reproductive age Have diagnosis of polycystic ovary syndrome by Rotterdam (at least 2 of 3 criteria) a. Oligomenorrhea (cycles lasting > 35 days) or amenorrhea (< 3 cycles in last 6 months) b. Clinical signs of hyperandrogenism or elevated total testosterone level c. Polycystic appearing ovaries Report sexual dysfunction Have no evidence of depression  Has chronic medical illness such as diabetes mellitus, hypertension, and previous venous embolism Taking any prescription medications for at least 3 months prior to entry into the study with the exception of allergy or occasional pain medications Has other etiologies of anovulation and hyperandrogenism, e.g., Cushings disease, thyroid dysfunction, elevated prolactin levels, sighs of congenital adrenal hyperplasia Has any contraindications to hormonal contraception
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 2.0-50.0,  Meningococcal With the subject (or his guardian's) informed consent and signed the informed consent The history, physical examination and clinical judgement were determined to be healthy and in accordance with the vaccination age of the product The Subject or his guardian could comply with the clinical study protocol Have not been inoculated with Meningococcal vaccine in the past six months and A + C meningococcal polysaccharide vaccine in the past two years Have not been inoculated with other preventive biological products Axillary temperature≤37.0 ℃  Children with the history of Neisseria meningitis Had allergies or serious adverse reactions of previous vaccination, such as allergies, urticaria, dyspnea, edema, abdominal pain, etc Had immune inhibitor therapy and cytotoxic therapy, inhaled corticosteroids in the past 6 months (not including allergic rhinitis corticosteroid aerosol therapy, patients with acute non concurrent dermatitis surface corticosteroid therapy) Have been accepted blood products in the past 3 months Have been inoculated with other research drugs or vaccines in the past month Have been inoculated with attenuated live vaccine in the past 14 days Have been inoculated with subunit or inactivated vaccine in the past 7 days Had any acute illness, the need for systemic application of antibiotics or antiviral treatment in the past 7 days Had fever in the past 3 days (axillary temperature≥38.0℃)  Have been diagnosed with abnormal coagulation function (such as the lack of coagulation factors, coagulation disorders and abnormal blood platelet), obvious bruises or coagulation disorders by physician diagnosis